Bio Green Med Solution, Inc. — Director's Dealing 2023

Dec 26, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2023-12-21

Reporting Person: Rombotis Spiro George (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-21	Common Stock	P	6070	$3.315	Acquired	68658	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-21	Warrants (right to buy)	$3.19	P	6070	Acquired	2030-12-21	Common Stock (6070)	Direct

Footnotes

F1: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.

F2: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant.